Urinary Peptidomic Profiling in Post-Acute Sequelae of SARS-CoV-2 Infection: A Case-Control Study
Dilara Guelmez, Justyna Siwy, Katharina Kurz, Ralph Wendt, Miroslaw Banasik, Bjorn Peters, Emmanuel Dudoignon, Francois Depret, Mercede Salgueira, Elena Nowacki, Amelie Kurnikowski, Sebastian Mussnig, Simon Krenn, Samuel Gonos, Judith Loffler-Ragg, Guenter Weiss, Harald Mischak, Manfred Hecking, Eva Schernhammer, Joachim Beige
Background
Post-acute sequelae of severe acute respiratory syndrome coronavirus 2-infection (PASC) is challenging to diagnose and treat, and its molecular pathophysiology remains unclear. Urinary peptidomics can provide valuable information on urine peptides that may enable improved and specified PASC diagnosis.
Methods
Using standardized capillary electrophoresis-MS, we examined the urinary peptidomes of 50 patients with PASC 10 months after COVID-19 and 50 controls including healthy individuals (n = 42) and patients with non-COVID-19-associated myalgic encephalomyelitis/chronic fatigue syndrome (n = 8). Based on peptide abundance differences between cases and controls, we developed a diagnostic model using a support vector machine.
Results
The abundance of 195 urine peptides among PASC patients significantly differed from that in controls, with a predominant abundance of collagen alpha chains. This molecular signature (PASC195), effectively distinguished PASC cases from controls in the training set [AUC of 0.949 (95% CI 0.900-0.998; p < 0.0001)] and independent validation set [AUC of 0.962 (95% CI 0.897-1.00); p < 0.0001)]. In silico assessment suggested exercise, GLP1-RA and MRA as potentially efficacious interventions.
Conclusions
We present a novel and non-invasive diagnostic model for PASC. Reflecting its molecular pathophysiology, PASC195 has the potential to advance diagnostics and inform therapeutic interventions.
Web | PDF | Preprint: MedRxiv | Open Access
Dilara Guelmez, Justyna Siwy, Katharina Kurz, Ralph Wendt, Miroslaw Banasik, Bjorn Peters, Emmanuel Dudoignon, Francois Depret, Mercede Salgueira, Elena Nowacki, Amelie Kurnikowski, Sebastian Mussnig, Simon Krenn, Samuel Gonos, Judith Loffler-Ragg, Guenter Weiss, Harald Mischak, Manfred Hecking, Eva Schernhammer, Joachim Beige
Background
Post-acute sequelae of severe acute respiratory syndrome coronavirus 2-infection (PASC) is challenging to diagnose and treat, and its molecular pathophysiology remains unclear. Urinary peptidomics can provide valuable information on urine peptides that may enable improved and specified PASC diagnosis.
Methods
Using standardized capillary electrophoresis-MS, we examined the urinary peptidomes of 50 patients with PASC 10 months after COVID-19 and 50 controls including healthy individuals (n = 42) and patients with non-COVID-19-associated myalgic encephalomyelitis/chronic fatigue syndrome (n = 8). Based on peptide abundance differences between cases and controls, we developed a diagnostic model using a support vector machine.
Results
The abundance of 195 urine peptides among PASC patients significantly differed from that in controls, with a predominant abundance of collagen alpha chains. This molecular signature (PASC195), effectively distinguished PASC cases from controls in the training set [AUC of 0.949 (95% CI 0.900-0.998; p < 0.0001)] and independent validation set [AUC of 0.962 (95% CI 0.897-1.00); p < 0.0001)]. In silico assessment suggested exercise, GLP1-RA and MRA as potentially efficacious interventions.
Conclusions
We present a novel and non-invasive diagnostic model for PASC. Reflecting its molecular pathophysiology, PASC195 has the potential to advance diagnostics and inform therapeutic interventions.
Web | PDF | Preprint: MedRxiv | Open Access